Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Tax year for HEMO is 31 December 2022. They have to publish their annual report by the end of April (LSE rule). The date of their annual report publication has nothing to do with their tax year.
OMG! I was not careful enough and looked at the board. What a pile of nonsense! IND is delayed because someone said it is. Vlad is bad because he does not tweet and he is also bad because he does tweet. HEMO is delaying RNS until the end of tax year (Dec 31, 2023!). Guys and Gals, have a life. HEMO is known to report when it has something to report. On the other hand, perhaps HEMO lost all money in the banking crises? Why don’t you entertain this idea? Is Vlad alive? Has anyone asked this question? What if he is dead or run away ( no tweets lately). What the hell is happening? Who is posting on LinkedIn that HEMO is hiring? Why are they hiring computer geeks? Are they making Apps now? These questions keep me awake. Reading this board makes me puke.
I checked all available to me sources to see if there was a date for IND submission. I cannot find any specific date. Where does the first week of February come from?
The speed/timing of IND submission does matter. The quality of the IND matters more than a specific date. I would assume that hemo is trying to do the best it can to present the cleanest and strongest application. Of course, there is a chance that they are lying and doing nothing to actually submit their IND. if that is what we are discussing here then we will have a clear answer soon as the company is scheduled to go through an audit for its annual report.
I would guess hemo is doing what it can to maximize its chances with the FDA. This may take some time (days or weeks). After all, the IND is a very complicated document.
I have no formed opinion on CBR. Based on the company’s RNSs it is something of high value. It remains to be seen what products will get developed and for what indications though. I think it is at the stage gene editing methods like CRISPER were a few years ago. First, it looks like the sky is the limit but then it all boils down to a specific application and how successful that application is. Check out Editas Medicine for example. $656M raised and not yet in the clinic. Sky is the limit though and the brightest minds are behind Editas.
I would give hemo a slack now. It is a tiny company with limited resources and limited experience dealing with the FDA. I am honestly surprised they made it that far.
Stu, I think it is somewhat stupid to claim something that is not confirmed by the company officially. It is like losing your own credibility for something that has no meaning. Do you care if that IND is filed tomorrow or in a few weeks? The only meaning of the precise date would be to be able to have an advantage in trading. I can care less ... I would not waste my breath arguing with the "gang of LTH's" either.
Mates, how do you know when the IND is supposed to be filed? Is there an official date? Why are you talking about a delay? I cannot see anything regarding a date in any RNS. Please explain.
The RNS reads: "The HEMO-CAR-T cells will also be tested by a third party to ensure they comply with a set of required quality attributes." where does it say "certify"? I read it as if there are some tests that can be done by a third party but not by hemo. It is unknown what these tests are and how long they take.
Stu, where did you read that a third party would have to certify PQ results?
I repeat my question. If Vlad is to blame for not delivering news every week, why don’t you vote him out? Why do you keep buying this stock (or are you buying it or selling it or whatever)?
If Vlad is to be blamed, then Vlad is to be sacked. Why don’t we vote home out?
Do you have a candidate to run the company?
@haywain you are right. A better example is Kite. It raised $335M from 2008 to 2017 when it was sold to Gilead for $11.9B. At that time Kite’s axi-cell CAR-T was under priority review by the FDA. HEMO raised less than 20M from 2015 to 2020. It is about to enter the clinic. I cannot understand how Vlad was able to make this happen. It all defies logic and experience of other companies. As far as I am concerned, HEMO is a miracle.
TYK2 inhibitor went into phase 3 clinical trials. To get there, Nimbus went through 8 financing rounds raising $427M since 2008. Hemo raised less than $20M over its lifetime. It takes serious money to get serious return. https://www.crunchbase.com/organization/nimbus-discovery/company_financials
@tuan6 your posts are verbal diarrhea! Go back into your advfn hole.
@All, I rarely post here. I cannot foresee what will happen with the SP. I can say though that based on what Hemo is announcing, they are at full speed toward their goal - the clinic.
Based on HEMO’s announcement https://hemogenyx.com/investors/investors/announcements/announcement/2022/1513/ they must be in the middle of the first engineering run. Hopefully, it is going to be successful and we will learn about it.
https://hemogenyx.com/investors/investors/announcements/announcement/2022/1513/
Do you think this man could be the source of millions shares recently sold?
https://news.italy24.press/local/amp/127740
https://twitter.com/vmsandler/status/1587120424386797569?s=46&t=ZtJGNjUYHc87zesB3tgb9Q
I see a stream of RNS from this company. The CEO is super active presenting at conferences and pushing the company forward. Most CEOs who are not pumpers engage 2-4 times a year as far as I know. I could understand if one would expect more updates from a company with 100-200 people but this spec has what, 8-10 people or so? How can one possibly demand more than what they have already achieved? I am lost.
Strange. I cannot find anything in their RNS about master cell lines. In any case, such thing as a master cell line is just an intermediary step that nobody announces. Why do you want them to announce it? I would also guess that it might be detrimental for the business to publicly disclose such things as master cell line.
What news do you expect? I see HEMO releases RNS every couple of weeks. They also post some videos with updates. There is going to be interim report some time this month. It looks like they are moving forward. Am I missing something?
ALL is not what HEMO is doing